After grabbing 2.0 million shares, the institutional investor is now in possession of 2.0 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 5.73% having worth around $2.22 million. Moreover, Sabby Capital LLC increased its share by 0.34 million to have a control over 0.34 million shares. And UBS Securities LLC raised its holdings to 0.1 million shares by acquiring 0.1 million shares or 0.29% of the stake.

AIkido Pharma Inc. (AIKI) concluded trading on 08/27/20 at a closing price of $0.66, with 1.25 million shares of worth about $0.83 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -10.29% during that period and on Thursday the price saw a loss of about -6.98%. Currently the company’s common shares owned by public are about 32.98M shares, out of which, 32.95M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 0 analysts are covering the AIKI stock and their offered price forecasts bring an average price target of $1802.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1802.25 and could fall to a lowest price of $1802.25. However, touching the estimated high of $1802.25 would mean a gain of 99.96% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

Vanguard Extended Market Index Fu, USAA Extended Market Index Fund, and Fidelity Nasdaq Composite Index F are the top 3 mutual funds which are holding stakes in AIkido Pharma Inc. Vanguard Extended Market Index Fu is currently holding 0.1 million shares of worth totaling $0.11 million. The company recently came buying 80300.0 shares which brought its stake up to 0.29% of the company’s outstanding shares. USAA Extended Market Index Fund bought 2971.0 shares, after which its hold over company’s outstanding shares expand to 0.02%, leaving 5226.0 shares with the mutual fund that have a worth of about $5801.0. Fidelity Nasdaq Composite Index F, after buying 4137.0 shares, have now control over 0.01% of the stake in the company. It holds 0.0 shares of worth $4592.0.

AIkido Pharma Inc. (NASDAQ: AIKI) started trading at $0.70, below -$0.01 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $0.66, or with a loss of -6.98%. Stock saw a price change of -10.29% in past 5 days and over the past one month there was a price change of -42.11%. Year-to-date (YTD), AIKI shares are showing a performance of -49.45% which decreased to -64.95% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.47 but also hit the highest price of $5.46 during that period. While comparing its average daily trading volume of 4.55 million shares, we see that about 1.25 million changed hands on the day. The stock is currently trading -29.87% below its 20-day simple moving average (SMA20), while that difference is down -29.54% for SMA50 and it goes to -32.40% lower than SMA200.

Altium Capital Management LP acquired 2.0 million shares of AIkido Pharma Inc. having value of about $2.22 million. AIkido Pharma Inc. (NASDAQ: AIKI) currently have 32.98M outstanding shares and institutions hold larger chunk of about 13.30% of that. Holding of mutual funds in the company is about 0.32% while other institutional holders and individual stake holders have control over 7.25% and — of the stake respectively.

The stock has a current market capitalization of $23.69M and its 3Y-monthly beta is at 2.07. It has posted earnings per share of -$2.07 in the same period. It has Quick Ratio of 30.20 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AIKI, volatility over the week remained 7.99% while standing at 10.35% over the month.

Analysts are in expectations that AIkido Pharma Inc. (AIKI) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter ESPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -282.90%.

Analysts at 0 brokerage firms have issued recommendations for the AIkido Pharma Inc. (AIKI)’s stock out of those 0 Wall Street analysts, 0 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.